The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
Autori
Jovanović, NikolaLazarević, Milica
Cvetković, Vladimir J.
Nikolov, Vesna
Kostić Perić, Jelena
Ugrin, Milena
Pavlović, Sonja
Mitrović, Tatjana
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
A single-institution observational study with 43 newly diagnosed diffuse gliomas defined the isocitrate dehydrogenase 1 and 2 (IDH1/2) gene mutation status and evaluated the prognostic relevance of the methylation status of the epigenetic marker O6-methylguanine-DNA methyltransferase (MGMT). Younger patients (50 years with surgical resection and IDH1/2-wildtype diffuse glioma), distinguished 10 (41.6%) methylated samples from 14 (58.4%) unmethylated samples. Finally, significant correlation between OS and methylation status was noticed (p ≈ 0.05). The OS of the hypermethylated group was 9.6 ± 1.77 months, whereas the OS of the unmethylated group was 5.43 ± 1.04 months. Our study recognized the MGMT promoter methylation status as a positive prognostic factor within the described homogenous cohort, although further verification in a larger population of diffuse gliomas is required.
Ključne reči:
IDH1 / IDH2 / MGMT / diffuse glioma / glioblastoma / MSP / qMSPIzvor:
International Journal of Molecular Sciences, 2022, 23, 21, 13034-Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200124 (Univerzitet u Nišu, Prirodno-matematički fakultet) (RS-MESTD-inst-2020-200124)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200042 (Univerzitet u Beogradu, Institut za molekularnu genetiku i genetičko inženjerstvo) (RS-MESTD-inst-2020-200042)
Institucija/grupa
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Jovanović, Nikola AU - Lazarević, Milica AU - Cvetković, Vladimir J. AU - Nikolov, Vesna AU - Kostić Perić, Jelena AU - Ugrin, Milena AU - Pavlović, Sonja AU - Mitrović, Tatjana PY - 2022 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1663 AB - A single-institution observational study with 43 newly diagnosed diffuse gliomas defined the isocitrate dehydrogenase 1 and 2 (IDH1/2) gene mutation status and evaluated the prognostic relevance of the methylation status of the epigenetic marker O6-methylguanine-DNA methyltransferase (MGMT). Younger patients (50 years with surgical resection and IDH1/2-wildtype diffuse glioma), distinguished 10 (41.6%) methylated samples from 14 (58.4%) unmethylated samples. Finally, significant correlation between OS and methylation status was noticed (p ≈ 0.05). The OS of the hypermethylated group was 9.6 ± 1.77 months, whereas the OS of the unmethylated group was 5.43 ± 1.04 months. Our study recognized the MGMT promoter methylation status as a positive prognostic factor within the described homogenous cohort, although further verification in a larger population of diffuse gliomas is required. T2 - International Journal of Molecular Sciences T2 - International Journal of Molecular Sciences T1 - The Significance of MGMT Promoter Methylation Status in Diffuse Glioma IS - 21 SP - 13034 VL - 23 DO - 10.3390/ijms232113034 ER -
@article{ author = "Jovanović, Nikola and Lazarević, Milica and Cvetković, Vladimir J. and Nikolov, Vesna and Kostić Perić, Jelena and Ugrin, Milena and Pavlović, Sonja and Mitrović, Tatjana", year = "2022", abstract = "A single-institution observational study with 43 newly diagnosed diffuse gliomas defined the isocitrate dehydrogenase 1 and 2 (IDH1/2) gene mutation status and evaluated the prognostic relevance of the methylation status of the epigenetic marker O6-methylguanine-DNA methyltransferase (MGMT). Younger patients (50 years with surgical resection and IDH1/2-wildtype diffuse glioma), distinguished 10 (41.6%) methylated samples from 14 (58.4%) unmethylated samples. Finally, significant correlation between OS and methylation status was noticed (p ≈ 0.05). The OS of the hypermethylated group was 9.6 ± 1.77 months, whereas the OS of the unmethylated group was 5.43 ± 1.04 months. Our study recognized the MGMT promoter methylation status as a positive prognostic factor within the described homogenous cohort, although further verification in a larger population of diffuse gliomas is required.", journal = "International Journal of Molecular Sciences, International Journal of Molecular Sciences", title = "The Significance of MGMT Promoter Methylation Status in Diffuse Glioma", number = "21", pages = "13034", volume = "23", doi = "10.3390/ijms232113034" }
Jovanović, N., Lazarević, M., Cvetković, V. J., Nikolov, V., Kostić Perić, J., Ugrin, M., Pavlović, S.,& Mitrović, T.. (2022). The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. in International Journal of Molecular Sciences, 23(21), 13034. https://doi.org/10.3390/ijms232113034
Jovanović N, Lazarević M, Cvetković VJ, Nikolov V, Kostić Perić J, Ugrin M, Pavlović S, Mitrović T. The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. in International Journal of Molecular Sciences. 2022;23(21):13034. doi:10.3390/ijms232113034 .
Jovanović, Nikola, Lazarević, Milica, Cvetković, Vladimir J., Nikolov, Vesna, Kostić Perić, Jelena, Ugrin, Milena, Pavlović, Sonja, Mitrović, Tatjana, "The Significance of MGMT Promoter Methylation Status in Diffuse Glioma" in International Journal of Molecular Sciences, 23, no. 21 (2022):13034, https://doi.org/10.3390/ijms232113034 . .